Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
These small steps can help you incorporate your injection into your life with less hassle
Months four through eight are the steady-progress stretch
Each 250 mcg dose equals 10 units
Using Retatrutide for the cutting phase of a traditional bulk and cut cycle could theoretically preserve more muscle than cutting without pharmaceutical assistance
Cholera Vaccine Dengue Fever Vaccine DTP Tick-Borne Encephalitis Vaccine Japanese Encephalitis Vaccine Hepatitis A Vaccine Hepatitis B Vaccine Travel Vaccines Cholera Vaccine The Cholera Vaccine helps protect against cholera, a bacterial infection spread through contaminated food and water in high-risk areas